The Undruggable Just Got Drugged: KRAS G12D Meets Its Match

Cancer researchers spent four decades staring at the KRAS G12D protein like a locksmith staring at a lock with no keyhole. They knew it was driving some of the deadliest cancers on the planet - roughly 40% of pancreatic cancers and about 5% of lung cancers - but nobody could figure out how to shut it off. The protein earned the label "undruggable," which in science is basically a polite way of saying, "We've tried everything and this thing just will not cooperate."

Then someone decided to stop picking the lock and blow up the whole door instead.

Wanted: Dead, Not Alive

A new drug called setidegrasib, published this week in The New England Journal of Medicine, takes a wildly different approach to the KRAS G12D problem. Instead of trying to block the protein from doing its job (the traditional strategy), setidegrasib slaps a molecular "destroy me" tag on it and hands it over to the cell's own recycling machinery. It's called a PROTAC - a proteolysis-targeting chimera - and it works like calling a tow truck on a car you can't hotwire. If you can't turn it off, just haul it away.

Here's why that matters: KRAS G12D is the most common KRAS mutation in pancreatic cancer, a disease with a five-year survival rate that barely cracks 10%. Pancreatic cancer doesn't respond well to immunotherapy. It laughs at most chemotherapy regimens. And until very recently, there was literally nothing that could target the specific molecular saboteur responsible for the majority of cases. Meanwhile, the G12C version of KRAS already has two FDA-approved drugs (sotorasib and adagrasib), leaving G12D patients watching from the sidelines like the kid picked last in dodgeball (Skoulidis et al., 2021; Chen et al., 2022).

What the Trial Actually Found

Dr. Wungki Park and colleagues enrolled 203 patients with previously treated advanced solid tumors harboring KRAS G12D mutations across sites in the US, Europe, Japan, and South Korea. The 600 mg intravenous dose - given once weekly - was selected as the sweet spot for phase 2 (Park et al., 2026).

Lung cancer (NSCLC): Among 45 patients, 36% had their tumors shrink meaningfully (partial response). Median progression-free survival hit 8.3 months, and an estimated 59% were still alive at one year. For a previously treated population with limited options, those are numbers that make oncologists sit up straighter in their chairs.

Pancreatic cancer: Twenty-one patients received setidegrasib as second- or third-line therapy (two-thirds were on their third treatment). Even in this tough-to-treat group, 24% responded, with a median overall survival of 10.3 months. To put that in perspective, second-line pancreatic cancer treatments typically measure survival in the "please don't ask" range.

The Side Effect Situation (Surprisingly Chill)

Every patient experienced some adverse event - you don't pump a novel protein-destroying agent into people without something happening - but the profile was remarkably tolerable. The most common issue? Infusion-related reactions in 80% of patients, which sounds scary until you learn these are mostly solved by pre-medicating with antihistamines. Think of it as the biological equivalent of your body saying, "Hey, what's this?" before settling down.

Nausea hit 30%, and grade 3+ events occurred in 42%, but here's the stat that matters: only 2 out of 76 patients at the selected dose had to stop treatment because of side effects. Two. In early-phase oncology, where drugs routinely get abandoned because patients can't tolerate them, that's exceptional (Park et al., 2026).

Why the "Destroy, Don't Block" Strategy is a Big Deal

Traditional kinase inhibitors work by sitting in a protein's active site and blocking it. The problem with KRAS is that it grips its fuel source (GTP) tighter than a toddler grips a candy bar - there's no room to wedge a drug in. PROTACs sidestep this entirely by recruiting the cell's proteasome, the molecular wood chipper that normally disposes of worn-out proteins, to chew up KRAS G12D specifically. Setidegrasib links KRAS G12D to an E3 ubiquitin ligase called VHL, essentially introducing them at a party and letting nature take its destructive course (Discovery of KRAS(G12D) selective degrader ASP3082).

The selectivity is impressive too - setidegrasib degrades KRAS G12D while leaving wild-type KRAS and over 9,000 other proteins alone. Precision like that suggests the side effects might stay manageable as the drug moves into larger trials.

What Comes Next

Astellas, the company behind setidegrasib, is gearing up for a phase 3 trial combining the drug with mFOLFIRINOX chemotherapy as first-line treatment for pancreatic cancer. Early combination data already looks promising: among 12 evaluable first-line pancreatic patients, the response rate was 58% with an 83% disease control rate. For a cancer that has humbled every therapeutic advance thrown at it for decades, those numbers border on unprecedented.

This isn't a cure. It's a phase 1 trial, the earliest clinical stage, and plenty of promising drugs have flamed out in later testing. But after 40 years of calling KRAS G12D "undruggable," having a drug that actually degrades it, shrinks tumors, and keeps patients on treatment feels less like a small step and more like someone finally kicking open a door that was never supposed to open.

References:

1. Park W, Kasi A, Spira AI, et al. Setidegrasib in advanced non-small-cell lung cancer and pancreatic cancer. N Engl J Med. 2026. DOI: 10.1056/NEJMoa2600752. PMID: 41879829

2. Skoulidis F, Li BT, Dy GK, et al. Sotorasib for lung cancers with KRAS p.G12C mutation. N Engl J Med. 2021;384(25):2371-2381. DOI: 10.1056/NEJMoa2103695

3. Chen H, Smaill JB, Liu T, et al. KRAS G12D targeted therapies for pancreatic cancer: Has the fortress been conquered? Front Oncol. 2022;12:1013902. DOI: 10.3389/fonc.2022.1013902. PMID: 36531078

4. Nagashima T, Inamura K, Nishizono Y, et al. Discovery of KRAS(G12D) selective degrader ASP3082. Commun Chem. 2025. DOI: 10.1038/s42004-025-01662-4

5. Spagnuolo A, Maione P, Gridelli C. KRAS G12C inhibition in solid tumors: biological breakthroughs, clinical evidence, and open challenges. Cancers. 2025;17(17):2803. DOI: 10.3390/cancers17172803

Disclaimer: The image accompanying this article is for illustrative purposes only and does not depict actual experimental results, data, or biological mechanisms.